Clinical Trial Update: Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating reconvalescent plasma and camostat mesylate started early in SARS-CoV-2 positive high-risk individuals; the study statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Infection
• Sars-cov-2 Acute Respiratory Disease

Drugs mentioned

• Camostat Mesylate (camostat mesylate)
• reconvalescent plasma

Snippet

Sponsor: Heinrich-Heine University, Duesseldorf | Conditions: Corona Virus Infection, SARS-CoV-2 Infection | Phase 2 | Status: COMPLETED